Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

324
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
324
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of comorbidity burden with cause-specific survival after CAR T therapy for large B-cell lymphoma.

Leukemia & lymphoma·2026
Same author

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).

Blood neoplasia·2026
Same author

Detection and classification of lymphoma from cell-free methylome data.

NPJ precision oncology·2026
Same author

Innovative approaches for managing relapsed or refractory peripheral T-cell lymphoma.

Expert opinion on pharmacotherapy·2026
Same author

Targeted therapy in early-stage classical Hodgkin lymphoma.

Blood·2026
Same author

Relapsed classic Hodgkin lymphoma; should all patients receive an autologous stem cell transplant? - the PRO.

Haematologica·2026

Related Experiment Video

Updated: Jun 23, 2025

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

10.0K

Optimizing salvage therapy for Hodgkin lymphoma: progress and future challenges.

Chathuri Abeyakoon1,2,3, John Kuruvilla1

  • 1Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.

Expert Review of Hematology
|June 25, 2024
PubMed
Summary

Achieving complete remission before stem cell transplant is crucial for treating relapsed classical Hodgkin lymphoma. Immune checkpoint inhibitors show promise in salvage therapy for improved outcomes.

Keywords:
Hodgkin lymphomabrentuximab vedotincheckpoint inhibitorsnovel agentsrelapsed and refractorysalvage therapy

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.8K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.0K

Related Experiment Videos

Last Updated: Jun 23, 2025

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

10.0K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.8K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.0K

Area of Science:

  • Hematology
  • Oncology
  • Nuclear Medicine

Background:

  • Classical Hodgkin lymphoma (cHL) management has advanced, yet one-third of patients relapse.
  • Novel agents and positron emission tomography (PET)-guided approaches are improving outcomes.
  • Salvage therapy for relapsed refractory cHL (RR-cHL) is evolving.

Purpose of the Study:

  • To discuss the evolving treatment paradigm in optimizing salvage therapy for RR-cHL.
  • To provide a vision for future treatment strategies.
  • To highlight key prognostic factors and emerging therapeutic options.

Main Methods:

  • Literature search on PubMed using relevant keywords.
  • Screening and evaluation of selected articles by the authors.
  • Review of current evidence on salvage regimens for RR-cHL.

Main Results:

  • Complete remission by 18F-flurodeoxyglucose (FDG)-PET pre-autologous stem cell transplantation (ASCT) is a critical prognostic factor.
  • Novel agents like brentuximab vedotin (BV) and immune checkpoint inhibitors (CPIs) are incorporated into salvage regimens.
  • Retrospective data suggest CPI-based regimens may offer superior event-free survival compared to conventional chemotherapy or BV-based therapy.

Conclusions:

  • Achieving a negative FDG-PET response pre-ASCT is a key goal for disease control and cure.
  • CPIs represent a promising avenue for salvage therapy in RR-cHL.
  • Further research, including randomized controlled trials, is needed to confirm the efficacy of novel agents.